Jobs
-
Finnish nanotechnology company Nanoform has named Gonçalo Rebelo de Andrade, former Hovione Business Development Manager for inhalation and respiratory product development, as Chief of Business Operations. The company recently announced that it is building a… Read more . . .
-
Orexo has announced results from a PK study of its OX124 naloxone nasal spray in 20 healthy volunteers that compared 4 development formulations of OX124 to Narcan naloxone nasal spray. According to the company, all… Read more . . .
-
Impel NeuroPharma has announced results from a Phase 1 PK trial of INP105 intranasal olanzapine demonstrating that the intranasal formulation achieved Tmax two times faster than Zyprexa intramuscular olanzapine and ten times faster than Zyprexa… Read more . . .
-
Senzer has announced that its breath-activated Systemic inhaled Delivery Device (SiDD) inhaler has won a 2018 Good Design award in the medical category. The Good Design Awards are presented by The Chicago Athenaeum: Museum of… Read more . . .
-
Biotech company Stem Cell Medicine (SCM) has announced that it licensed intranasal MSC-exo technology for the treatment of autism spectrum disorder (ASD) from Ramot, the Tel Aviv University Business Engagement Center. Preclinical studies have shown… Read more . . .
-
According to a report in Israeli financial newspaper Globes, Tel Aviv-based Syqe Medical has raised $50 million in a financing round led by Shavit Capital for continued development of its medicinal plants inhaler. Shavit Capital… Read more . . .
-
The FDA has approved Acorda’s Inbrija levodopa DPI for the treatment of OFF episodes in Parkinson’s disease patients taking carbidopa/levodopa, the company said. Inbrija is expected to be available to patients in the US in… Read more . . .
-
According to Teva, the FDA has approved the company’s sNDA for ProAir Digihaler dry powder albuterol smart inhaler for the treatment or prevention of bronchospasm in patients aged 4 and over. The FDA initially approved… Read more . . .
-
NPXe has announced the enrollment of the first patient in a Phase 3 study of Xenex inhaled xenon gas for the treatment of post cardiac arrest syndrome (PCAS). The FDA granted Fast Track designation to… Read more . . .
-
The annual Drug Delivery to the Lungs meeting once again experienced significant growth in attendance and sponsorship, as DDL 2018 drew more than 850 attendees and 110 exhibitors to the Edinburg International Conference Centre. Many… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany